Ranolazine dihydrochloride (CVT 303 dihydrochloride) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine dihydrochloride 还是脂肪酸氧化的部分抑制剂。
| 生物活性 |
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor. |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究 |
Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.
|
||||||||||||||||
| 分子式 |
C24H35Cl2N3O4
|
||||||||||||||||
| 分子量 |
500.46
|
||||||||||||||||
| CAS号 |
95635-56-6
|
||||||||||||||||
| 中文名称 |
盐酸雷诺嗪
|
||||||||||||||||
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
| 储存方式 |
|
||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (99.91 mM) H2O : ≥ 50 mg/mL (99.91 mM) * "≥" means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
|
||||||||||||||||
| 临床试验 |
|
||||||||||||||||
| 科研文献 |
纯度： 98%
客服小K 
客服小K
Data Sheet
